Prostaglandin H2 (PGH(2))

A cyclic endoperoxide intermediate produced by the action of CYCLOOXYGENASE on ARACHIDONIC ACID. It is further converted by a series of specific enzymes to the series 2 prostaglandins.

Also Known As:

Networked: 136 relevant articles (4 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Urade, Yoshihiro: 5 articles (06/2011 - 12/2002)
2.	Ruan, Ke-He: 3 articles (12/2019 - 06/2015)
3.	So, Shui-Ping: 3 articles (12/2019 - 06/2015)
4.	Inoue, Tsuyoshi: 3 articles (10/2007 - 12/2002)
5.	Matsumura, Hiroyoshi: 3 articles (10/2007 - 12/2002)
6.	Li, Qun-Ying: 2 articles (12/2019 - 01/2018)
7.	Ling, Qing-Lan: 2 articles (12/2019 - 01/2018)
8.	Akasaka, Hironari: 2 articles (01/2018 - 06/2015)
9.	Wolin, Michael S: 2 articles (01/2017 - 11/2007)
10.	Cummins, Robert: 2 articles (05/2014 - 03/2011)

Related Diseases

1.	Thrombosis (Thrombus) 02/01/1998 - "Elevated platelet TXA2/PGH2 receptor levels and enhanced sensitivity of platelet aggregation to TXA2 predict early arterial graft thrombosis. " 02/01/1998 - "Preoperative platelet TXA2/PGH2 receptor density was higher (Bmax, 3100 +/- 1300 vs 1500 +/- 1100 sites/platelet [mean +/- SD]; p = 0.004) in the five patients who had graft thrombosis within 3 months. " 02/01/1998 - "Early graft thrombosis was more likely in patients with a platelet TXA2/PGH2 receptor density greater than 3000 sites/platelet (odds ratio, 76; 95% confidence interval, 3.9 to 1500) or an EC50 for U46619 less than 30 nmol/L (odds ratio, 16; 95% confidence interval, 1.4 to 180). " 04/01/1984 - "Because 13-APA does not interfere with arachidonic acid metabolism, the ability of 13-APA to suppress thrombus formation is presumably due to direct antagonism of TXA2/PGH2 at the platelet receptor level. " 01/01/1988 - "Thus far, evidence is presented for intrinsic platelet hyperactivity (at the PG-peroxidase reaction of the COx pathway) in patients with unstable angina: the resulting increase in PGH2 and TxA2 synthesis, alone or in combination with decreased PGI2 sensitivity, may account for a facilitated thrombus formation."
2.	Hypertension (High Blood Pressure) 11/01/2000 - "Collectively, these findings suggest that in hypertension, endothelium-derived ET and PGH(2)/TxA(2) increase the Ca(2+) sensitivity of the contractile apparatus of arteriolar smooth muscle; thus, the similar increases in [Ca(2+)](i) in response to the elevation of intraluminal pressure elicit greater myogenic constriction." 08/01/1997 - "Sympathetic nervous system and hypertension during prolonged TxA2/PGH2 receptor activation in rats." 10/01/1996 - "Therefore, the aim of these studies was to compare the antihypertensive efficacy of an ANG II type I (AT1) and a TxA2/PGH2 receptor antagonist during different phases of 2K,1C hypertension. " 03/01/1999 - "These results provide evidence that hypertension elicits alterations in levels of arachidonic acid metabolites, including PGH2 and PGI2. " 12/01/1997 - "Infusion of the TxA2/PGH2 mimetic, U-46,619, into conscious rats leads to hypertension that is potentiated by a high-salt intake. "
3.	Coronary Occlusion 03/01/1991 - "We determined in the present study if this dose of aspirin can also reverse the protective effects of the thromboxane A2/PGH2 receptor antagonist SQ 30,741 in the same model of coronary occlusion and reperfusion. "
4.	Coronary Stenosis (Coronary Artery Stenosis) 03/01/1989 - "The object of this study was to test the hypothesis that administration of both serotonin S2 and thromboxane A2-prostaglandin H2 (PGH2) receptor antagonists provides significant protection against epinephrine-induced cyclic coronary artery flow variations in open chest, anesthetized dogs with severe proximal coronary artery stenosis and endothelial injury. "
5.	Inflammation (Inflammations) 07/01/2010 - "Despite biochemical evidence of PGH(2) substrate diversion to potential bronchomodulator PGs, deletion of mPGES-1 had little effect on ozone-induced airway inflammation or airway hyper-responsiveness. " 07/01/2005 - "PGHS mediates the formation of prostaglandin H2, the precursor for a number of prostaglandins which are important in a wide variety of biological processes, including inflammation, blood clotting, renal function, and tumorigenesis. " 01/01/2021 - "mPGES-1 is an inflammation-inducible enzyme that converts PGH2 into PGE2. " 12/01/2005 - "Prostaglandin E2 (PGE2) is one of the most important mediators in the processes of inflammation, and is converted from PGH2 by various kinds of PGE synthases (PGESs). " 12/01/1977 - "However, direct evidence is presented to show that an oxygen equivalent released in the enzymatic conversion of PGG2 to PGH2 is a prime factor in inflammation."

Related Drugs and Biologics

1.	Prostaglandin H2 (PGH(2))
2.	Thromboxane A2 (A2, Thromboxane)
3.	Thromboxanes
4.	Aspirin (Acetylsalicylic Acid)
5.	Serotonin (5 Hydroxytryptamine)
6.	Sodium
7.	Tissue Plasminogen Activator (Alteplase)
8.	Epinephrine (Adrenaline)
9.	Antihypertensive Agents (Antihypertensives)
10.	KW 3635

Related Therapies and Procedures

1.	Percutaneous Coronary Intervention
2.	Drug-Eluting Stents
3.	Transplantation
4.	Therapeutics
5.	Electrodes (Electrode)